BIOCRYST PHARMACEUTICALS, INC. Cost of Goods Sold (Deprecated 2018-01-31)
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Cost of Goods Sold (Deprecated 2018-01-31) of $1.14 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-03-12
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.14M.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2015-12-31 was $7.00K.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2015-09-30 was $1.35M.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $1.14M, a 50.28% decline from fiscal 2016.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $2.30M, a 67.91% increase from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $1.37M, a 136700.00% increase from fiscal 2014.
- BIOCRYST PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $1.00K.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.14M derived: sum of 2 quarters · filed 2018-03-12 | $1.14M 10-K · filed 2018-03-12 | |
| 2017-09-30 | $1.14M 10-Q · filed 2017-11-08 | $1.14M 10-Q · filed 2017-11-08 | ||
| 2016-12-31 | $2.30M 10-K · filed 2018-03-12 | |||
| 2015-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.35M derived: sum of 2 quarters · filed 2018-03-12 | $1.35M derived: sum of 3 quarters · filed 2018-03-12 | $1.37M 10-K · filed 2018-03-12 |
| 2015-09-30 | $1.35M 10-Q · filed 2016-11-08 | $1.35M derived: sum of 2 quarters · filed 2016-11-08 | $1.36M 10-Q · filed 2016-11-08 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $15.00K 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $15.00K 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $1.00K 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |